Zelluna (ZLNA.OL) Stock Analysis & AI Equity Report
Zelluna (ZLNA.OL) overview
Zelluna (ZLNA.OL) stock analysis and AI equity research. For the latest completed financial year, 2024, Zelluna reported revenue of NOK 0m and operating profit of NOK 0m; the year-end share price was 2.33 NOK and market capitalisation was N/A. Zelluna is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Zelluna's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-06. Data will be refreshed during report generation.
About Zelluna
Zelluna ASA is a Norwegian biotechnology company developing allogeneic, off-the-shelf T cell receptor-guided natural killer, or TCR-NK, cell therapies for solid cancers. Its lead program, ZI-MA4-1, targets the MAGE-A4 antigen and is in clinical development. The company’s value driver is its proprietary platform for scalable manufacturing of cell therapies.
Generate the Zelluna report
Zelluna is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Zelluna and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.